In a similar manner, Sasaki and colleagues combined electrical pacing with CPVT- and control-hiPSC-CMs to validate S107, a drug that stabilizes the closed state of the RYR2, as potential therapeutic agent for CPVT1 [131]. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia 1.